Blopress Under Attack In Japan Generic Listing
This article was originally published in PharmAsia News
Japan has listed in the national insurance reimbursement tariff its latest batch of generic drugs, awarding prices to 521 products from 72 companies, including versions of Takeda's blockbuster antihypertensive Blopress.
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.